Alcon Announces Full-Year Sales Guidance and Strategic Growth Drivers
During its third quarter 2026 earnings call, Alcon (ALC) provided full-year net sales growth guidance of approximately 6% alongside expectations for double-digit core earnings-per-share growth. Despite a 2% decline in U.S. implantable lens revenue due to competitor trials, the company is countering with new technologies like Vivity Pro and TruPlus to defend its premium cataract surgery market share. The company is also focusing on long-term customer lock-in through surgical equipment placement, notably reaching 40% of U.S. teaching hospitals with its UNITY VCS system. Additionally, Alcon's acquisition of Neurotech Pharmaceuticals introduces ENCELTO, a cell therapy for Macular Telangiectasia Type 2, which is projected to reach peak sales between $250 million and $400 million.
Tickers: $ALC
Topics: earnings report market share medical devices sales guidance